![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Imfinizi for Head and Neck Cancer Fails in Late-Stage Study
AstraZeneca’s Imfinizi for Head and Neck Cancer Fails in Late-Stage Study
![failed text](https://www.fdanews.com/ext/resources/test/Drug-Images4/Failed-text-stamp.gif?t=1598999898&width=430)
February 10, 2021
AstraZeneca (AZ)’s immunotherapy drug Imfinzi (durvalumab) failed to improve overall survival for head and neck squamous cell carcinoma (HNSCC) patients in a global phase 3 trial.
The monoclonal antibody treatment was compared with chemotherapy plus Bristol Myers Squibb’s Erbitux (cetuximab) as a first-line treatment for HNSCC patients whose tumors expressed high levels of programmed cell death-ligand 1.
Dave Fredrickson, executive vice president of AZ’s oncology unit, said that insights from the disappointing study will advance the company’s “understanding and application” of immunotherapy.
Upcoming Events
-
21Oct